April 21, 2014 6:15 AM ET


Company Overview of Lux Biosciences, Inc.

Company Overview

Lux Biosciences, Inc., a biotechnology company, engages in the development and commercialization of medications for ophthalmic diseases in the United States and internationally. Its products comprise LUVENIQ, an oral form of calcineurin inhibitor voclosporin, which is used for the treatment of non-infectious uveitis; LX214, a topical formulation that contains mixed nanomicelles of voclosporin for ophthalmic use; LX212, a bioerodible polymer implant containing voclosporin; and LX213, a bioerodible/isotechnika implant. The company was incorporated in 2005 and is based in Jersey City, New Jersey.

3 Second Street

Harborside Financial Center Plaza 10

14th Floor

Jersey City, NJ 07302

United States

Founded in 2005





Key Executives for Lux Biosciences, Inc.

Chief Executive Officer
Age: 57
Co-Founder and Senior Vice President of Project Planning & Analysis
Co-Founder and Chief Medical Officer
Co-Founder and Chief Operating Officer
President of Europe Region and Managing Director of Lux Biosciences GmbH
Compensation as of Fiscal Year 2013.

Lux Biosciences, Inc. Key Developments

Lux Biosciences, Inc. Completes Enrollment in Phase 3 Uveitis Study

Isotechnika Pharma Inc. announced that Lux Biosciences, Inc. has completed patient enrollment in its Phase 3 clinical study using voclosporin (branded as Luveniq(TM) by Lux) for the treatment of non-infectious uveitis, a cause of vision loss and long-term disability. Lux anticipates that data from the Phase 3 study will be available early in the first quarter of 2013. The Phase 3 study is a six-month, randomized, multi-center, double-masked, controlled trial to evaluate the efficacy and safety of Luveniq for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye. The study includes 155 patients and is taking place at 56 sites across North America, Europe and Brazil. The primary endpoint of the trial is the change from baseline in vitreous haze at 12 weeks or at the time of treatment failure, if earlier. Lux anticipates that the results from this trial, if positive, will address the U.S. Food and Drug Administration's request for additional clinical information as part of the Complete Response letter regarding the New Drug Application ("NDA") for Luveniq issued in August 2010, and will support a resubmission of the NDA under priority review early in 2013. Lux additionally expects the trial results, if positive, to support a regulatory filing to the European Medicines Agency for Luveniq. The product has received Orphan Drug designation in both Europe and the United States for the treatment of non-infectious uveitis.

Similar Private Companies By Industry

Company Name Region
BioAvenge United States
Cebix Incorporated United States
LiveLeaf, Inc. United States
Parallel Solutions, Inc. United States
Hadron Systems, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lux Biosciences, Inc., please visit www.luxbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.